JP2024523443A5 - - Google Patents
Info
- Publication number
- JP2024523443A5 JP2024523443A5 JP2023578727A JP2023578727A JP2024523443A5 JP 2024523443 A5 JP2024523443 A5 JP 2024523443A5 JP 2023578727 A JP2023578727 A JP 2023578727A JP 2023578727 A JP2023578727 A JP 2023578727A JP 2024523443 A5 JP2024523443 A5 JP 2024523443A5
- Authority
- JP
- Japan
- Prior art keywords
- lyophilized
- sequence
- formulation
- activatable
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213026P | 2021-06-21 | 2021-06-21 | |
| US63/213,026 | 2021-06-21 | ||
| PCT/US2022/033958 WO2022271544A1 (en) | 2021-06-21 | 2022-06-17 | Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523443A JP2024523443A (ja) | 2024-06-28 |
| JP2024523443A5 true JP2024523443A5 (cg-RX-API-DMAC10.html) | 2025-06-18 |
Family
ID=82403446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578727A Pending JP2024523443A (ja) | 2021-06-21 | 2022-06-17 | 高濃度凍結乾燥生物製剤の再構成時間を減少させるためのスクロース、マンニトールおよびグリシンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250332251A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4359438A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024523443A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240024929A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117500834A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022271544A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0654897A (ja) * | 1992-08-08 | 1994-03-01 | Chemo Sero Therapeut Res Inst | フィブリノーゲン含有製剤 |
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| JP4340540B2 (ja) * | 2002-01-18 | 2009-10-07 | 旭化成ファーマ株式会社 | 可溶性トロンボモジュリン高濃度含有製剤 |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| AU2011325134B2 (en) * | 2010-11-05 | 2014-10-23 | Novartis Ag | Methods of treating rheumatoid arthritis using IL-17 antagonists |
| ES2962373T3 (es) * | 2016-04-13 | 2024-03-18 | Medimmune Llc | Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas |
| CN110072890B (zh) * | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| TW202112354A (zh) * | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 遮蔽抗體調配物 |
-
2022
- 2022-06-17 EP EP22738290.0A patent/EP4359438A1/en active Pending
- 2022-06-17 KR KR1020247001907A patent/KR20240024929A/ko active Pending
- 2022-06-17 CN CN202280043695.4A patent/CN117500834A/zh active Pending
- 2022-06-17 JP JP2023578727A patent/JP2024523443A/ja active Pending
- 2022-06-17 WO PCT/US2022/033958 patent/WO2022271544A1/en not_active Ceased
- 2022-06-17 US US18/572,479 patent/US20250332251A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8795686B2 (en) | Stable, dried rotavirus vaccine, compositions and process for preparation thereof | |
| AU2007251122B2 (en) | A composition useful as a vaccine | |
| RU2695523C2 (ru) | Вакцины против вирусов свиней, стабильные в жидкой форме | |
| EP0417193B1 (en) | Freeze-dried formulation for antibody products | |
| FR2742756A1 (fr) | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation | |
| KR910005888B1 (ko) | 동결건조 b형 간염 왁진의 제조방법 | |
| JPH01279843A (ja) | 凍結乾燥ａ型肝炎ワクチン | |
| KR20240046787A (ko) | 지질 나노-에멀젼 입자에 흡착된 mRNA의 동결건조 제제 | |
| AU2013208693B2 (en) | Compositions and methods for treating viral infections | |
| CN114752703A (zh) | 一种新型冠状病毒核酸的冻干型检测试剂及其制备方法 | |
| JP2023539476A5 (cg-RX-API-DMAC10.html) | ||
| CN102892409B (zh) | 用于保存铝盐佐剂和铝盐-佐剂化疫苗的方法 | |
| BR112012000588A2 (pt) | composição, composição líquida, composição liofilizada e método para produzir um rotavirus atenuado | |
| HK1207312A1 (en) | Temperature stable vaccine formulations | |
| CN114224851A (zh) | 一种人白细胞介素10-Fc融合蛋白的冻干粉制剂及制备方法 | |
| KR20200000497A (ko) | Vlp 안정화된 백신 조성물 | |
| JP2023538669A5 (cg-RX-API-DMAC10.html) | ||
| CN114317700B (zh) | 荧光pcr试剂冻干保护剂、冻干方法及应用 | |
| JPS63115825A (ja) | 中和糖タンパク質のペプチド | |
| Dong et al. | Thermostability of a trivalent, capsomere-based vaccine for human papillomavirus infection | |
| CN116831993B (zh) | 抗菌蛋白的冷冻干燥制剂 | |
| CN1050987A (zh) | 用于口服的稳定的免疫原组合物 | |
| JP2024521329A5 (cg-RX-API-DMAC10.html) | ||
| JP2015091791A (ja) | インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法 | |
| CN113368063B (zh) | 一种注射用重组白细胞抑制因子和水蛭肽嵌合蛋白冻干制剂及其制备方法 |